cellular targeting
Sanofi adds new inflammatory target to growing Nurix tie-up
Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup
Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment
UnitedHealthcare CEO Brian Thompson Fatally Shot in Targeted Attack Outside New York City Hotel
UnitedHealthcare, CEO Brian Thompson, targeted killing, New York City, hotel shooting, investor meeting
Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs
Blue Earth Therapeutics, Series A financing, radiohybrid RLTs, Phase II studies, targeted therapies, lutetium, alpha emitter.
Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805
Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment